Table 4.
Histone demethylase inhibitors and siRNA for overcoming drug resistance
| Regulatory factor | Enzyme | Cancer type | Mechanism | Reference |
|---|---|---|---|---|
| Arborinine | LSD1 | Gastric cancer | Inhibit the expression of LSD1 and EMT | 345 |
| HCI-2509 | LSD1 | Prostate cancer | Inhibit colony-forming ability and reduce the expression of C-MYC to inhibit proliferation | 346 |
| GSK2879552 | LSD1 | Hepatoma | Reduce the level of LINC01134 | 271 |
| NCL1 | LSD1 | Breast cancer | Inhibit LSD1 and cell proliferation and autophagy | 347,348 |
| NSC636819 | KDM4A | Lung, breast, and prostate cancer | Increase the expression of DR5 and TRAIL and activate exogenous apoptosis | 349 |
| ML324 | KDM4B | Prostate cancer | Inhibit the demethylation activity of KDM4B | 298 |
| JIB-04 | KDM4A | leukemia | Increase H3K36me3 level and restore the sensitivity to cytosine arabinoside | 350 |
| ZINC33576 | KDM5A | Breast Cancer | Inhibit the demethylation activity of KDM5A to H3K4 and block the cell in G1 phase | 352 |
| PBIT | KDM5B | Non-small cell carcinoma | Inhibit lung cancer stem cells like phenotype to regulate cell sensitivity | 308 |
| CPI-455 | KDM5A | APL | Promote cell differentiation induced by all-trans retinoic acid | 358 |
| GSK-J4 | KDM6A; KDM6B | Colorectal cancer | Inhibit the expression of Notch2 and increase the sensitivity to oxaliplatin | 329 |
| KDM2B | Hepatoma | Reduce the self-renewal ability of stem cells | 282 | |
| Circ0006168 | KDM3C | ESCC | Positively regulate the expression of KDM3C | 290 |